Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Novo Nordisk A/S (NVO) Stock Price
Headlines about Novo Nordisk A/S (NYSE:NVO) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novo Nordisk A/S earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.7261999976875 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern’s scoring:
- Shikiar Asset Management Inc. Sells 7000 Shares of Novo Nordisk A/S (NVO) (wisdomsave.com)
- Cornerstone Advisors Inc. Has $151000 Position in Novo Nordisk A/S (NVO) (vothemes.com)
- Novo Nordisk A/S : – Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 (4-traders.com)
- Eli Lilly and Co (NYSE:LLY) Tanks As Novo Nordisk A/S (ADR) (NYSE:NVO) Diabetes Drug Succeeds In Key Trial (4-traders.com)
- Novo Nordisk’s diabetes drug succeeds in key trial (Aug 16) (finance.yahoo.com)
Shares of Novo Nordisk A/S (NVO) traded down 0.35% during mid-day trading on Friday, hitting $45.18. 1,447,308 shares of the stock traded hands. The firm’s 50-day moving average is $43.03 and its 200-day moving average is $39.17. The stock has a market cap of $112.06 billion, a price-to-earnings ratio of 18.57 and a beta of 0.63. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $47.98.
The company also recently declared an annual dividend, which will be paid on Tuesday, August 29th. Investors of record on Monday, August 21st will be paid a $0.336 dividend. This represents a yield of 1.07%. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date of this dividend is Friday, August 18th. Novo Nordisk A/S’s dividend payout ratio is presently 36.44%.
A number of research analysts have recently commented on NVO shares. Zacks Investment Research raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Tuesday, April 25th. TheStreet raised shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a report on Tuesday, May 2nd. Finally, BidaskClub upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, June 15th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $53.00.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Novo Nordisk A/S (NVO) Stock Price” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/19/novo-nordisk-as-nvo-given-daily-news-impact-rating-of-0-07-updated-updated-updated.html.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.